Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Acid-related diseases

Short-term as well as long-term studies with pantoprazole-sodium have proven its excellent efficacy in healing acid-related diseases, preventing relapse, and providing rapid relief from disease-related symptoms. Direct comparison with other anti-secretory drugs showed that pantoprazole-sodium is significantly more effective than H2-receptor blockers and is either equivalent to or better than other clinically used PPIs [39]. [Pg.132]

Modlin IM, Sachs G. Acid related diseases Biology and treatment. 2nd edn. Lippincot, Williams Wilkins, Philadelphia, 2004. [Pg.134]

Berardi RR, Welage LS. Proton-pump inhibitors in acid-related diseases. Am J Health Syst Pharm 1998 55(21) 2289-98. [Pg.2976]

Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, panto-prazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000 40 52-62. [Pg.648]

History of Therapeutic Approaches to Acid Related Diseases... [Pg.131]

There are several components of this barrier currently under consideration as contributing to the pathogenesis of acid related disease the mucous layer, HCOj- secretion, and cellular factors providing cytoprotection, such as prostaglandin... [Pg.178]

Acute treatment of acid related diseases often requires a decision as to the nature of the drug to be used and the route of administration. In the vast majority of cases, oral administration of the standard formulation of available drugs is the route of choice, but in some instances, where really rapid and virtually complete inhibition of acid secretion is desired, oral dosing of the capsule or tablet forms may be less effective than required. There are then two general decisions to be made. Are liquid forms available Can the capsule form be changed to a liquid suspension and administered as such by swallowing or via nasogastric tube Or is the patient in a situation in which intravenous therapy is best or even mandatory ... [Pg.306]

Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995 40 24S-49S. [Pg.439]

Acid related diseases biology and treatment / Irvin M. Modlin, George Sachs.--2nd ed. p. cm. [Pg.524]

This book is focused on gastric biology. It takes a historical path to introduce present-day discoveries and concepts and uses these concepts to explain modern-day treatment of acid related disease. Indeed, without an understanding of the direction from which we have come, it will not be easy to perceive where our future direction lies. [Pg.529]

Chapter 1 History of Therapeutic Approaches to Acid Related Diseases Chapter 2 Inhibition of the Histamine-2 Receptor Chapter 3 Inhibition of the Gastric Acid Pump Section 4 The Biology of Acid Related Disease... [Pg.532]

Treatment of 26 duodenal ulcer patients with 40 mg of omeprazole daily for 4 weeks resulted in ulcer healing in 25 out of the 26 patients [36]. After solving many problems during the research leading to omeprazole, it seemed to represent a successful new principle in the treatment of acid-related diseases. New problems were, however, waiting around the comer. [Pg.19]

Successful treatment of acid-related diseases is significantly correlated with suppression of 24-h gastric acid secretion [28-30]. Three key parameters which determine the effect of treatment with antisecretory drugs have been identified through a series of meta-analyses of pharmacodynamic gastric secretory studies and clinical therapeutic trials the degree of suppression of acid secretion, the duration of acid suppression over the 24-h period and the length of therapy in weeks [28-30]. [Pg.67]

Shamburek RD, Schubert ML (1994) Structure and function of the stomach. Role of the proton pump. In RH Hunt (ed) Proton pump inhibitors and acid-related diseases. Adis International, Osaka... [Pg.74]

Sachs G (1997) Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17(1) ... [Pg.75]

Huang JQ, Hunt RH (1996) pH, healing rate and symptom relief in acid-related diseases. Yale JBiol Med 69 159-174... [Pg.76]

Brunner G, Creutzfeldt W, Harke U, Lamberts R (1989) Efficacy and safety of long-term treatment with omeprazole in patients with acid related diseases resistant to ranitidine. Can J Gastroenterol 3 (Suppl A) 72-76... [Pg.110]

As proton pump inhibitors (PPIs) have revolutionized treatment of acid-related diseases, alone, or in drug combinations for eradication of Helicobacter pylori, it does not come as a surprise that the first representative of the class, omeprazole, has been joined by a number of similar agents including lansoprazole, pantoprazole and, as the latest entry, rabeprazole. It is the purpose of this overview to delineate differences and similarities and put them into the perspective of clinical relevance. Some of these aspects are covered in broader detail in other chapters of this book. [Pg.143]

PPIs share quite a number of properties, and discriminating features are rather subtle. Even where easily identifiable, they may interest more from theoretical than practical points of view. Their high efficacies and wide margins of safety make them first-line drugs in the treatment of acid-related diseases, even after the advent of H, / y/or/-related therapy. [Pg.153]

Socio-economic impact of acid-related diseases... [Pg.238]

See other pages where Acid-related diseases is mentioned: [Pg.198]    [Pg.198]    [Pg.59]    [Pg.232]    [Pg.115]    [Pg.115]    [Pg.116]    [Pg.132]    [Pg.87]    [Pg.35]    [Pg.629]    [Pg.429]    [Pg.35]    [Pg.367]    [Pg.135]    [Pg.139]    [Pg.141]    [Pg.143]    [Pg.169]    [Pg.171]    [Pg.353]    [Pg.508]    [Pg.523]    [Pg.527]    [Pg.528]    [Pg.63]    [Pg.65]    [Pg.69]    [Pg.91]   
See also in sourсe #XX -- [ Pg.367 ]



SEARCH



© 2024 chempedia.info